Clinical Trials · NCT01876849
An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 275
- Start date
- Dec 2003
- Locations
- 1 site, United States
- Primary endpoint
- Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events.